Please use this identifier to cite or link to this item:
|Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase
|Borrell Pagès, Maria
Canals i Coll, Josep M.
Cordelières, Fabrice P.
Parker, J. Alex
Pineda Martí, José Ramón
Bryson, Elzbieta A.
Cheetham, Michael E.
Alberch i Vié, Jordi
|Corea de Huntington
Degeneració del sistema nerviós
|American Society for Clinical Investigation
|There is no treatment for the neurodegenerative disorder Huntington disease (HD). Cystamine is a candidate drug; however, the mechanisms by which it operates remain unclear. We show here that cystamine increases levels of the heat shock DnaJ-containing protein 1b (HSJ1b) that are low in HD patients. HSJ1b inhibits polyQ-huntingtin¿induced death of striatal neurons and neuronal dysfunction in Caenorhabditis elegans. This neuroprotective effect involves stimulation of the secretory pathway through formation of clathrin-coated vesicles containing brain-derived neurotrophic factor (BDNF). Cystamine increases BDNF secretion from the Golgi region that is blocked by reducing HSJ1b levels or by overexpressing transglutaminase. We demonstrate that cysteamine, the FDA-approved reduced form of cystamine, is neuroprotective in HD mice by increasing BDNF levels in brain. Finally, cysteamine increases serum levels of BDNF in mouse and primate models of HD. Therefore, cysteamine is a potential treatment for HD, and serum BDNF levels can be used as a biomarker for drug efficacy.
|Reproducció del document publicat a http://dx.doi.org/10.1172/JCI27607
|It is part of:
|Journal of Clinical Investigation, 2006, vol. 116, núm. 5, p. 1410-1424.
|Appears in Collections:
|Articles publicats en revistes (Biomedicina)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.